Navigation Links
Typical IBD patients not represented in research studies
Date:8/22/2012

Major randomized controlled trials of new therapies for inflammatory bowel disease (IBD) are conducted on patients who are not typical of those who physicians see in day-to-day practice, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association (AGA).

The two major, often debilitating, illnesses that are recognized as IBD are ulcerative colitis and Crohn's disease. The introduction of biologics the most prescribed medications for IBD patients have dramatically impacted the ability to manage disease activity. However, a substantial percentage of IBD patients will have no response to these medications or lose response over time. This fact not only highlights the need for additional investigation of therapeutic targets, but also strategies to identify the optimal scenario for greatest therapeutic effect.

"Many outpatients with moderate-to-severe inflammatory bowel disease may not qualify for trials of new treatment options," said Christina Ha, MD, of the Johns Hopkins School of Medicine and lead author of this study. "Because of the heterogeneity of the inflammatory bowel disease patient population in terms of age of onset, disease behavior and severity, many patients may not meet the strict entry criteria for clinical trial participation. However, we often presume similar therapeutic effect among our clinic patients as demonstrated in clinical trials."

Researchers from the Johns Hopkins School of Medicine, Mount Sinai School of Medicine and Dartmouth-Hitchcock Medical Center performed a retrospective cohort study of 206 adult patients with moderate-to-severe IBD who went to the Mount Sinai Medical Center for an adjustment of their medical therapy from January 2008 to June 2009. Of these patients, only 31.1 percent would have been eligible to participate in a randomized controlled clinical trial of biologics. Reasons for exclusion included structuring or penetrating Crohn's disease, high-dose intake of steroids, comorbidities or prior exposure to biologics, or treatment with topical therapies.

Results from randomized clinical trials form the basis for FDA approval of treatments, expert recommendations and guidelines for the management of IBD patients, and are currently the best approach available to study treatment effects. However, by limiting the available pool of potential study patients through strict inclusion and exclusion criteria in an effort to maximize clinical trial results, these trial results may have limited applicability in the real-world doctor's office.

In addition, limiting selection criteria requires larger study populations, longer durations of follow-up observation and substantially greater cost. However, shifting to a more pragmatic-based approach with minimal study exclusions may help physicians generalize study results to their day-to-day practice as well as support randomized controlled trial findings in a more common clinical practice setting.


'/>"/>
Contact: Alissa J. Cruz
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. MR enterography is option for pediatric patients with Crohn disease
2. 2 Tests May Improve Heart Patients Care, Studies Suggest
3. Doctors Who Self-Refer to Radiation Clinics Add to Patients Burden: Study
4. Breast density does not influence breast cancer death among breast cancer patients
5. Newer Psoriasis Drugs May Lower Heart Attack Risk for Patients
6. Scientists to investigate preventing life-threatening complications in transplant patients
7. New Drug Appears to Extend Survival in Advanced Prostate Cancer Patients
8. Pre-test genetic counseling increases cancer knowledge for BRCA patients
9. Urology-owned radiation oncology self-referral can increase patients travel distance for treatment
10. Nurses as effective as doctors in treatment of HIV patients
11. Newer Bone Drug Better for Advanced Breast Cancer Patients: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: